Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision

Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision

Source: 
Biopharma Reporter
snippet: 

A survey from Spherix gathered reactions from US neurologists after the US Centers for Medicare & Medicaid Services (CMS) announced its National Coverage Determination for monoclonal antibodies against amyloid for the treatment of Alzheimer’s.